To assess the specificity of the RF predictor for trastuzumab, we validated the RF predictor on 34 HER2-positive and 54 HER2-negative breast cancer patients who did not receive trastuzumab in the same clinical trial. This evidence concerns the gene ERBB2 and breast carcinoma.